Doctors should closely monitor patients with GPP for signs of PG, including a thorough assessment of painful ulcers of undetermined origin. A diagnosis of generalized pustular psoriasis (GPP) is ...
1 Department of Cardio Thoracic and Vascular Surgery, All India Institute of Medical Sciences, Raipur, India. 2 Department of Cardio Thoracic and Vascular Surgery, Sri Padmavathi Children’s Heart ...
InflaRx ( (IFRX)) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma gangrenosum (PG), a rare, difficult-to-treat ulcerative ...
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
JENA, Germany, Dec. 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today outlined ...
Pyoderma gangrenosum lesion regression after dapsone treatment. However, after two weeks, the patient’s hematological condition deteriorated, presenting with a hemoglobin level of 7 g/dL, white blood ...
(A) Oval and elongated yeast-like structures in the deep dermis. (PAS, ×400). (B) Patient’s cat with nasal ulceration diagnosed as sporotrichosis. Only 10 published cases of PGLS were found in the ...
A new study published in the Journal of Drugs in Dermatology has found that heightened awareness and early diagnosis of pyoderma gangrenosum (PG) during pregnancy can avoid severe maternal and fetal ...
InflaRx N.V. (NASDAQ:IFRX) on Wednesday announced that the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results